Regeneron pens Inovio I-O combo cocktail pact for aggressive brain tumors

The trial will use three different types of meds in the hope that it can knock down this difficult-to-treat disease.

Regeneron and Inovio have signed up to a new combo trial deal that will see the pair add PD-1 inhibitor REGN2810 to Inovio’s immune activator and T-cell activator drugs in patients with newly-diagnosed glioblastoma multiforme (GBM), a hard-to-treat type of brain cancer.

The phase 1b/2a open-label trial, which should begin this year, will have 50 patients and focus on overall survival, as well as progression-free survival and immunological impact. This aggressive cancer has few treatments options and can hit younger patients, making any med that can show strong efficacy a much-needed advance. 

The study will combine Regeneron’s PD-1 inhibitor REGN2810 (which is also being studied in other cancers with long-term partner Sanofi) and Inovio's T-cell activator INO-5401 as well as its immune activator INO-9012 in brain cancer.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The test, across 30 sites in the U.S., will combine Regeneron’s PD-1 inhibitor, REGN2810, with Inovio’s INO-5401 T-cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding IL-12.

Under the pact, the trial will be conducted and funded solely by Inovio, based upon a mutually agreed upon study design, while Regeneron will supply REGN2810.

Inovio and Regeneron will jointly conduct immunological analyses in support of the study. Financial terms were not disclosed.

“Regeneron’s approach to oncology includes evaluating the combination of innovative therapies that act on diverse pathways and targets,” said Israel Lowy, M.D., Ph.D, VP of translation sciences and oncology at Regeneron.

“Using our PD-1 inhibitor as a therapeutic backbone alongside Inovio’s T cell-generating therapies offers a new path for exploration and heightens the potential to develop new, desperately-needed treatment options for patients.”

“I am a strong believer in this combination regimen approach in immuno-oncology: use Inovio immunotherapies to generate killer T-cells to turn 'cold' tumors into 'hot' tumors, then block T cell suppression via checkpoint inhibition," added J. Joseph Kim, Ph.D, Inovio's president and CEO. “This step with INO-5401 is very important for us in 2017, as we believe INO-5401 has the potential to be a powerful cancer immunotherapeutic in combination with promising checkpoint inhibitors such as Regeneron's REGN2810, and we look forward to investigating its potential for GBM and multiple other challenging cancers.”

Inovio, which has a market cap of just over $470 million, was up 2.6% this morning on the news. 

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.